Orgenesis Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.


Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending June 29, 2021 was $51.4 Million (a -5.84% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) decreased by -40.73%
  • Annual Shareholders Equity (Total) for 2020 was $52.6 Million (a 860.0% increase from previous year)
  • Annual Shareholders Equity (Total) for 2019 was $5.48 Million (a -80.68% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $28.4 Million (a -1.04% decrease from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of Orgenesis Inc.

Most recent Shareholders Equity (Total)of ORGS including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of Orgenesis Inc.

Orgenesis Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $51.36 $54.55
2020 $52.58 $86.66 $88.23 $89.66 $52.58
2019 $6.08 $11.1 $16.75 $21.4 $5.48
2018 $28.65 $29.96 $25.8 $19.48 $28.35
2017 $14.12 $11.25 $9.9 $14.12
2016 $12.49 $10.58 $10.58 $0.0 $12.5
2015 $-6.44 $-6.44
2014 $-2.97 $-2.98
2013 $-2.03 $-2.03
2012 $-0.28 $-0.28
2011 $-0.28

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.